Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Boston, Massachusetts, that specializes in developing and commercializing innovative therapies based on novel tetracycline chemistry. The company’s lead product, NUZYRA, is a once-daily oral and intravenous broad-spectrum antibiotic designed for treating community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens. Another significant product, SEYSARA, is specifically formulated for the treatment of moderate to severe acne vulgaris. Paratek has received Qualified Infectious Disease Product designation from the U.S. Food and Drug Administration for its lead antibiotic, which is significant in addressing antibiotic resistance. The company has established collaborative agreements with various organizations, including Zai Lab and Allergan, as well as a partnership with the U.S. Army Medical Research Institute to explore its antibiotics against infectious disease agents. Founded in 1996, Paratek Pharmaceuticals remains committed to addressing serious public health threats through its advanced therapeutic solutions.